While pertuzumab is moving ahead in the FDA approval process, an additional indication for denosumab might be halted.

  >   Web Exclusives

Upfront zoledronic acid is superior to delayed use in postmenopausal women with early breast cancer who are being treated with the aromatase inhibitor letrozole.

Oncology & Biotech News   >   Breast Cancer

Antiresorptive medicines used to reduce the loss of bone mass related to bone metastases or treatment toxicity are associated with an increased risk of ONJ.

Onc Nurse   >   Conference Highlights

Bone disease occurs in about 84% of patients with multiple myeloma and is responsible for a great deal of morbidity, including pain, hypercalcemia, compromised quality of life, and pathological fracture.

Oncology & Biotech News   >   Conference Highlights

A single dose of radiotherapy and a single injection of ibandronate provided similar pain relief from bone metastases in men with metastatic prostate cancer.

Oncology & Biotech News   >   Conference Highlights

Physicians and patients with castration-resistant prostate cancer (CRPC) have an increasing number of treatment options that improve outcomes.

Oncology & Biotech News   >   Conference Highlights